NCT02695459: Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

NCT02695459
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Chemotherapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior chemotherapy for metastatic disease; Patients with prior therapy of mTOR inhibitors (e.g. sirolimus, temsirolimus, deforolimus, everolimus); Patients with history or clinical evidence of brain metastases
https://ClinicalTrials.gov/show/NCT02695459

Comments are closed.

Up ↑